Clorox (NYSE:CLX) PT Raised to $148.00 at UBS Group

Posted by on Apr 8th, 2023

Clorox (NYSE:CLX – Get Rating) had its price objective increased by research analysts at UBS Group from $140.00 to $148.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm presently has a “sell” rating on the stock. UBS Group’s price objective points to a potential downside of 6.19% from the stock’s current price.

A number of other brokerages have also weighed in on CLX. Wells Fargo & Company boosted their price objective on shares of Clorox from $125.00 to $135.00 and gave the stock an “underweight” rating in a report on Tuesday, January 3rd. JPMorgan Chase & Co. boosted their price objective on shares of Clorox from $126.00 to $135.00 and gave the stock an “underweight” rating in a report on Friday, January 13th. Barclays lowered their price objective on shares of Clorox from $110.00 to $108.00 and set an “underweight” rating for the company in a report on Monday, February 6th. Citigroup initiated coverage on shares of Clorox in a report on Thursday, February 16th. They issued a “neutral” rating and a $155.00 price objective for the company. Finally, Jefferies Financial Group boosted their price objective on shares of Clorox from $140.00 to $145.00 and gave the stock a “hold” rating in a report on Wednesday, February 1st. Seven investment analysts have rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $143.00.

Clorox Trading Up 0.2 %

Shares of Clorox stock opened at $157.76 on Thursday. Clorox has a 1 year low of $120.50 and a 1 year high of $160.59. The firm has a market cap of $19.49 billion, a PE ratio of 45.07, a PEG ratio of 3.15 and a beta of 0.30. The company has a debt-to-equity ratio of 5.04, a current ratio of 0.86 and a quick ratio of 0.47. The company has a 50 day simple moving average of $153.37 and a two-hundred day simple moving average of $145.82.

Clorox (NYSE:CLX – Get Rating) last announced its earnings results on Thursday, February 2nd. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.66 by $0.32. Clorox had a net margin of 6.16% and a return on equity of 89.97%. The business had revenue of $1.72 billion during the quarter, compared to analyst estimates of $1.66 billion. During the same period in the previous year, the business posted $0.66 earnings per share. Clorox’s revenue for the quarter was up 1.4% on a year-over-year basis. Analysts expect that Clorox will post 4.23 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Clorox by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 14,685,046 shares of the company’s stock valued at $2,041,661,000 after purchasing an additional 185,012 shares during the period. BlackRock Inc. grew its position in shares of Clorox by 5.6% in the 3rd quarter. BlackRock Inc. now owns 10,964,049 shares of the company’s stock worth $1,407,673,000 after buying an additional 580,982 shares during the period. State Street Corp grew its position in shares of Clorox by 9.6% in the 2nd quarter. State Street Corp now owns 8,907,083 shares of the company’s stock worth $1,255,721,000 after buying an additional 778,269 shares during the period. Geode Capital Management LLC grew its position in shares of Clorox by 2.8% in the 4th quarter. Geode Capital Management LLC now owns 2,624,490 shares of the company’s stock worth $367,648,000 after buying an additional 71,240 shares during the period. Finally, Federated Hermes Inc. grew its position in shares of Clorox by 11.1% in the 3rd quarter. Federated Hermes Inc. now owns 2,161,323 shares of the company’s stock worth $277,492,000 after buying an additional 215,425 shares during the period. 79.12% of the stock is owned by hedge funds and other institutional investors.

About Clorox

(Get Rating)

The Clorox Co engages in the manufacture and marketing of consumer and professional products. It operates through the following business segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment consists of cleaning products, professional products and vitamins, minerals and supplements mainly marketed and sold in the United States.

See Also

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.